{"brief_title": "Study of CEP-701 in Treatment of Prostate Cancer", "brief_summary": "The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.", "detailed_description": "A serological PSA response is defined as a reduction from baseline PSA serum concentration of at least 50%, which is confirmed by a second PSA value 28 or more days later.", "condition": "Prostate Cancer", "intervention_type": "Drug", "intervention_name": "CEP-701", "criteria": "Inclusion Criteria: - at least 18 yrs of age - diagnosis of adenocarcinoma of the prostate - no detectable metastatic disease as assessed by bone and CT scans - has increasing serum PSA concentrations - life expectancy of at least 3 months - ECOG of 0 or 1 - has been withdrawn from antiandrogen therapy for at least 6 weeks prior to entering screening period Exclusion Criteria: - has asymptomatic disease - has active GI ulceration or bleeding - has been treated with non-hormonal systemic anticancer therapy or has received radiation within 4 weeks of baseline visit - bilirubin >2x ULN or ALT or AST >2xULN or serum creatinine >1.5mg/dL - hemoglobin <9g/dL or platelets below 100,000/uL or ANC below 1500/uL - receiving treatment for HIV with protease inhibitors - has had prior malignancy within past 5 yrs with exception of resected basal or squamous cell carcinomas of the skin - has used investigational drug with previous one month", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00081601.xml"}